期刊文献+

伴有JAK2 V617F突变的慢性中性粒细胞白血病1例并文献复习 被引量:4

Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation
下载PDF
导出
摘要 目的:探讨伴有JAK2基因V617F突变的慢性中性粒细胞白血病(CNL)的实验室特征。方法:通过骨髓涂片进行细胞形态学分析诊断;采用实时荧光定量PCR方法检测BCR-ABL融合基因;实时荧光定量PCR方法及DNA测序方法检测JAK2 V617F突变;RHG显带进行常规染色体核型分析。结果:细胞形态学诊断为慢性中性粒细胞白血病;BCR/ABL融合基因为阴性;存在JAK2 V617F杂合突变;染色体分析结果为正常核型。结论:JAK2 V617F突变在慢性中性粒细胞白血病中很少见,具有该突变的CNL患者有较长的生存期,JAK2 V617F突变可能提示预后良好。 Objective:To investigate the laboratory character of chronic neutrophilic leukemia(CNL) with an associated V617F JAK2 tyrosine kinase mutation.Methods: To diagnoze CNL by cell morphology,detect BCR-ABL fusion gene by real-time quantitative PCR,and V617F JAK2 tyrosine kinase mutation by real-time quantitative PCR and DNA sequencing;To analyze chromosome karyotype.Results: CNL was diagnosed by cell morphology.BCR-ABL fusion gene(negative);existence of V617F JAK2 tyrosine kinase mutation,normal karyotype were observed.Conclusion: V617F JAK2 tyrosine kinase mutation is rare in CNL,CNL with an associated V617F JAK2 tyrosine kinase mutation has a long survival and may predict good prognosis.
出处 《现代肿瘤医学》 CAS 2012年第5期1017-1019,共3页 Journal of Modern Oncology
基金 沈阳市科学技术计划项目(编号:F10-218-1-00)
关键词 慢性中性粒细胞白血病 JAK2V617F突变 预后 chronic neutrophilic leukemia V617F JAK2 tyrosine kinase mutation prognosis
  • 相关文献

参考文献10

  • 1Elliott MA,Dewald GW,Teffer A,et al.Chronic neutrophilic leuke-mia(CNL):a clinical,pathologic and cytogetic study[J].Leuke-mia,2001,15(1):35.
  • 2Elliott MA,Hanson CA,Dewald GW,et al.WHO-defined chronicneutrophilic leukemia:a long-term analysis of 12 cases and acritical review of the literature[J].Leukemia,2005,19(2):313-317.
  • 3Saharinen P,Vihinen M,Silvennoinen O.Autoinhibition of JAK2tyrosine kinase is dependent on specific regions in its pseudokinasedomain[J].Mol Biol Cell,2003,14:1448-1459.
  • 4Baxter EJ,Scott LM,Campbell PJ,et al.Acquired mutation of thetyrosine kinase JAK2 in human myeloproliferative disorders[J].Lancet,2005,36(5):1054-1061.
  • 5Kralovics R,Passamonti F,Buser A,et al.A gain-of-functionmutation of JAK2 in myeloproliferative disorders[J].N Engl JMed,2005,35(2):1779-1790.
  • 6McClure R,Mat M,Lasho T.Validation of two clinically useful as-says for evaluation of JAK2 V617F mutation in chronic myeloprolif-erative disorders[J].Leukemia,2006,20(1):168-171.
  • 7Jones AV,Kriel S,Zoi K,et al.Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders[J].Blood,2005,10(6):2162-2168.
  • 8Steensma DP,Dewald GW,Lasho TL,et al.The JAK2 V617F acti-vating tyrosine kinase mutation is an infrequent event in both"a-typical"myeloproliferative disorders and the myelodysplastic syn-drome[J].Blood,2005,10(6):1207-1209.
  • 9Reilly JT.Chronic neutrophilic leukaemia:a distinct clinical Entity[J]?Br J Haematol,2002,11(6):10-18.
  • 10Donald P,Mc Lornan,Melanie J.Chronic neutrophilic leukemiawith an associated V617F JAK2 tyrosine kinase mutation[J].Haematologica,2005,90:1696-1697.

同被引文献92

  • 1ZOtIMBOS NC, SYMEONIDIS A,KOURAKLI-SYMEONIDIS A.Chronic neut-rophilic leukemia with dysplastic features: a new variant of the myelodysplastic syndromes? [ J ]. Acta Haematol, 1989,82(3) :156 - 160.
  • 2SWERDLOW SH, CAMPO E, HARRIS NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M 1.4th ed. Lyon : IARC press,2008 : 14 - 367.
  • 3JASON GOTLIBL, JULIA E. MAXSON, TRACY I. George, and Jeffrey W. Tyner. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment [ J ]. Blood September,2013,122 (10) : 1707 - 1711.
  • 4JABBOUR E, MATHISEN MS, O'BRIEN S. 10 years of progress in chronic myelogenous leukemia[ J ]. J Natl Compr Canc Netw,2012,10(9) :1049 - 1053.
  • 5Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms : The 2008 World Health Organization criteria and point-of-care diagnostic algorithms [ J ]. Leukemia, 2008,22 ( 1 ) : 14 -22.
  • 6Kako S, Kanda Y, Sato T, et al. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nerous system infiltration after unrelated bone marrow transplantation [ J ]. Am J Hematol, 2007,82 : 386- 390.
  • 7Pham C T. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol, 2006, 6(7): 541-550.
  • 8Smith J A. Neutrophils, host defense, and inflammation: a double- edged sword. J Leukoc Biol, 1994, 56(6): 672-686.
  • 9Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, 133(3421): 571-573.
  • 10Joyce J A. Therapeutic targeting of the tumor microenvironment. Cancer Cell, 2005, 7(6): 513-520.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部